{"id":"adjuvanted-rsvpref3-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a prefusion-stabilized form of the RSV F protein (PreF3), which is a key surface antigen that triggers neutralizing antibodies and cellular immunity. The adjuvant component enhances the immunogenicity of the vaccine by activating innate immune responses. This combination aims to provide robust protection against RSV disease, particularly in older adults and other high-risk populations.","oneSentence":"RSVPreF3 is a recombinant respiratory syncytial virus (RSV) fusion (F) protein vaccine designed to elicit protective immune responses against RSV infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:40.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) disease in adults"}]},"trialDetails":[{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT07050732","phase":"PHASE2","title":"Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-12-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":170},{"nctId":"NCT07203365","phase":"PHASE3","title":"RSV Immunogenicity Study in the Elderly (RISE)","status":"RECRUITING","sponsor":"Karin Karin Loré","startDate":"2025-08-25","conditions":"RSV Immunisation","enrollment":65},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT04657198","phase":"PHASE2","title":"Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-12-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adjuvanted RSVPreF3 vaccine","genericName":"Adjuvanted RSVPreF3 vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"RSVPreF3 is a recombinant respiratory syncytial virus (RSV) fusion (F) protein vaccine designed to elicit protective immune responses against RSV infection. Used for Prevention of respiratory syncytial virus (RSV) disease in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}